BioNTech SE/$BNTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Ticker
$BNTX
Sector
Primary listing
Employees
6,772
Headquarters
Website
BioNTech SE Metrics
BasicAdvanced
$26B
-
-$1.67
1.24
-
Price and volume
Market cap
$26B
Beta
1.24
52-week high
$129.27
52-week low
$81.20
Average daily volume
1.1M
Financial strength
Current ratio
8.607
Quick ratio
8.366
Long term debt to equity
1.174
Total debt to equity
1.457
Interest coverage (TTM)
-42.71%
Profitability
EBITDA (TTM)
-575.037
Gross margin (TTM)
79.76%
Net profit margin (TTM)
-11.98%
Operating margin (TTM)
-25.82%
Effective tax rate (TTM)
11.18%
Revenue per employee (TTM)
$500,840
Management effectiveness
Return on assets (TTM)
-2.14%
Return on equity (TTM)
-1.84%
Valuation
Price to revenue (TTM)
7.629
Price to book
1.38
Price to tangible book (TTM)
1.53
Price to free cash flow (TTM)
-8.582
Free cash flow yield (TTM)
-11.65%
Free cash flow per share (TTM)
-12.384
Growth
Revenue change (TTM)
6.98%
Earnings per share change (TTM)
-31.82%
3-year revenue growth (CAGR)
-48.60%
3-year earnings per share growth (CAGR)
-68.32%
What the Analysts think about BioNTech SE
Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.
Bulls say / Bears say
The acquisition of CureVac for approximately $1.25 billion in an all-stock deal will bolster BioNTech’s mRNA-based oncology pipeline and consolidate its technological leadership in cancer immunotherapies (Reuters).
The $1.5 billion upfront collaboration with Bristol Myers Squibb for the bispecific antibody BNT327 validates BioNTech’s oncology expertise and provides significant near-term non-dilutive funding for clinical development (Reuters).
A planned £1 billion ($1.33 billion) investment in the U.K., including £129 million in government grants, expands BioNTech’s R&D footprint and accelerates personalized cancer therapy trials, underlining strong governmental support (Reuters).
Despite Q2 revenue doubling, BioNTech reaffirmed full-year 2025 guidance of €1.7 billion to €2.2 billion, implying a material decline from €2.75 billion in 2024 and signaling sluggish recovery of core vaccine sales (Reuters).
The settlement of CureVac’s patent dispute for $740 million plus single-digit royalties on future U.S. vaccine sales could strain BioNTech’s margins and weigh on free cash flow generation in its vaccine franchise (Reuters).
A recent U.S. CDC advisory change to no longer broadly promote COVID-19 vaccinations risks reducing demand for Comirnaty and heightening revenue volatility in BioNTech’s primary product line (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
BioNTech SE Financial Performance
Revenues and expenses
BioNTech SE Earnings Performance
Company profitability
BioNTech SE News
AllArticlesVideos
Mizuho's Jared Holz: There's not much value left in vaccine stocks
CNBC Television3 weeks ago
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Market Watch4 weeks ago
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
Benzinga1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioNTech SE stock?
BioNTech SE (BNTX) has a market cap of $26B as of October 10, 2025.
What is the P/E ratio for BioNTech SE stock?
The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 0 as of October 10, 2025.
Does BioNTech SE stock pay dividends?
No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of October 10, 2025.
When is the next BioNTech SE dividend payment date?
BioNTech SE (BNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioNTech SE?
BioNTech SE (BNTX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.